ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "observation and rheumatoid arthritis (RA)"

  • Abstract Number: 536 • 2018 ACR/ARHP Annual Meeting

    Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study

    Masahiro Tada1, Yutaro Yamada2, Koji Mandai3 and Noriaki Hidaka4, 1Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan, 2Orthopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Orthopaedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 4Orthopaedic surgery, Osaka City General Hospital, Osaka, Japan

    Prevalence and relative factors for frailty in patients with RA from a prospective observational study Background/Purpose: Frailty is defined as degradation of physical and cognition…
  • Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting

    Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)

    Klaus Krüger1, Carlo Selmi2,3, Alain Cantagrel4, Miguel A. Abad5, Ulrich Freudensprung6, Mourad Farouk Rezk6 and Janet Addison7, 1Medical Centre of Rheumatology, Munich, Germany, 2Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, 3BIOMETRA Department, University of Milan, Milan, Italy, 4Center of Rheumatology of CHU, Toulouse, France, 5FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, 6Biogen International GmbH, Zug, Switzerland, 7Biogen Idec, Maidenhead, United Kingdom

    Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
  • Abstract Number: 1039 • 2017 ACR/ARHP Annual Meeting

    Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity

    Brian Sauer1, Jacob R. Stever1, Chia-Chen Teng, MS1, Neil Accortt2, David Collier2 and Grant Cannon1, 1Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Current guidelines encourage the measurement of rheumatoid arthritis (RA) disease activity to achieve a low disease state (treat-to-target). Many RA patients with documented moderate…
  • Abstract Number: 1364 • 2017 ACR/ARHP Annual Meeting

    Incidence of Rheumatoid Arthritis in a Cohort of First Degree Relatives from the Studies of the Etiology of Rheumatoid Arthritis

    Diraj R. Karnani1, Lindsy J. Forbess2, Michael Weisman3, Kevin D. Deane4, V. Michael Holers5 and Jill M. Norris6, 1Department of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, 2Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 3Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, 4Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 5Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, 6Department of Epidemiology, Colorado School of Public Health, Aurora, CO

    Background/Purpose: First-degree relatives (FDRs) of patients with rheumatoid arthritis (RA) are at increased risk for developing RA compared to the general population. The purpose of…
  • Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting

    Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials

    Daniel Erhardt1, Brian Sauer2, Chia-Chen Teng3, Ted R. Mikuls4, Jeffrey R. Curtis5, Derek Tang6, Bradley S. Stolshek6 and Grant W. Cannon1, 1Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 3HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 4University of Nebraska Medical Center, Omaha, NE, 5University of Alabama at Birmingham, Birmingham, AL, 6Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…
  • Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting

    Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry

    Nobunori Takahashi1, Toshihisa Kojima1, Koji Funahashi2 and Naoki Ishiguro3, 1Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, 2Nagoya University Hospital, Nagoya, Japan, 3Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan

    Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…
  • Abstract Number: 130 • 2015 ACR/ARHP Annual Meeting

    Disease Activity Patterns in Incident Onset Rheumatoid Arthritis Patients in the First 3-Years of Follow up

    Mark Tatangelo1, George A. Tomlinson2, Bindee Kuriya3 and Claire Bombardier4, 1University of Toronto, Toronto, ON, Canada, 2Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 3Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 4Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: Disease progression in longitudinal studies of rheumatoid arthritis (RA) is usually assessed by examining a measure of disease over time fixed time intervals. We…
  • Abstract Number: 42 • 2015 ACR/ARHP Annual Meeting

    Does the Risk of Mortality in Patients with RA Change over Time or Disease Duration?

    Kaleb Michaud1,2, Sofia Pedro2, Bryant R. England3 and Frederick Wolfe2, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Observational studies have shown an increased risk of mortality in patients with RA, though none have done so with patients from all 50 US…
  • Abstract Number: 2414 • 2014 ACR/ARHP Annual Meeting

    Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non-Interventional Study

    Karl Heinz Goettl1, Markus Gaubitz2, Andreas Krause3, Udo Lendl4, Ralph Lippe4, Thomas Meng4 and Peter-Andreas Loeschmann5, 1Joint practice for internal medicine, Passau, Germany, 2Academy of manual diagnostic at University of Münster, Münster, Germany, 3Konigstr. 63, Immanuel Krankenhaus Berlin, Berlin, Germany, 4Pfizer Pharma GmbH, Berlin, Germany, 5Loeschmann, Berlin, Germany

    Background/Purpose Although a combination with MTX is recommended for all biologics, data from different registries around the world show that in real life around 30%…
  • Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting

    Serious Infection Risk By Treatments and Types in Patients with RA

    Kaleb Michaud1,2, Sofia Pedro1, Andre Kalil3, Ted R. Mikuls4 and Frederick Wolfe1, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 3Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.